Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy (Q40385047)

20 September 2017

1 reference

title

Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy (English)

1 reference

20 September 2017

J E Oesterling

1 reference

20 September 2017

H C Ruckle

1 reference

20 September 2017

G G Klee

series ordinal

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 1994

1 reference

20 September 2017

1 reference

20 September 2017

1 reference

20 September 2017

1 reference

20 September 2017

page(s)

69-79

1 reference

Ability of preoperative serum prostatespecific antigen value to predict pathologic stage and DNA ploidy Influence of clinical stage and tumor grade

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

The Use of Prostate-Specific Antigen in Staging Patients With Newly Diagnosed Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate Specific Antigen and Local Recurrence after Radical Prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

The value of serum prostate specific antigen determinations before and after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Effect of Adjuvant Radiation Therapy on Prostate Specific Antigen Following Radical Prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Measurement of serum prostate specific antigen using IMx prostate specific antigen assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Immunoreactive prostatic specific antigen in male periurethral glands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate Specific Antigen after Irradiation for Prostatic Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Androgen effect on prostate specific antigen secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961615-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)61615-2

1 reference

20 September 2017

1 reference